Picture loading failed.

Anti-FCGRT therapeutic antibody (Pre-made Rozanolixizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Rozanolixizumab (UCB7665) is an investigational humanized monoclonal IgG antibody being developed by UCB for the treatment of myasthenia gravis (MG), a neuromuscular condition thought to be triggered by an autoimmune response.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-498-1mg 1mg 3090
GMP-Bios-ab-498-10mg 10mg 21890
GMP-Bios-ab-498-100mg 100mg 148000
GMP-Bios-ab-498-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-FCGRT therapeutic antibody (Pre-made Rozanolixizumab biosimilar,Whole mAb)
INN Name Rozanolixizumab
TargetFCGRT
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI Structure6fgb:HL
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2016
Year Recommended2017
CompaniesUCB
Conditions Approvedna
Conditions ActiveChronic inflammatory demyelinating polyradiculoneuropathy;Idiopathic thrombocytopenic purpura;Myasthenia gravis
Conditions DiscontinuedImmunological disorders
Development Techna